Assessment of the Changes in Cortical and Medullary Renal Blood Flow During Exercise in Healthy Subjects Using Contrast Enhanced Ultrasound

NCT ID: NCT02672722

Last Updated: 2017-05-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-31

Study Completion Date

2017-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Renal parenchymal blood flow can be divided in cortical and medullary blood flow. Changes and factors affecting renal medullary blood flow have not been studied in detail previously as investigators/doctors did not have tools to monitor renal medullary blood flow in vivo. Since Trueta first described renal medullary blood flow, multiple attempts have been made to study renal medullary blood flow using invasive methods. Recently renal medullary blood flow measurement using contrast US has emerged as a promising technique that investigators can use to study renal medullary blood flow in vivo. In this study investigators are aiming to study changes in renal parenchymal (cortical and medullary) blood flow with exercise in healthy subject.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study requires a screening day and two visits on separate days to the Clinical Research Unit (CRU). Three visits total.

Screening Visit:

1. The subjects will undergo detailed history and physical examination.
2. The inclusion and exclusion criteria will be reviewed.
3. The details of the study procedures, potential risks and benefits will be reviewed with each subject and all potential questions will be answered.
4. Subjects' understating of all details of the study components will be ascertained and they will be asked to sign the informed consent form.
5. A copy of the signed informed consent will be placed in study file and another copy will be provided to each subject.
6. The study visit day will be scheduled within 2 weeks of the screening day.
7. All subjects will be asked to arrive on their first study day after an overnight fast. They will be instructed to avoid caffeine and exercise for 24 hours.

Study Day #1 The subjects will arrive in the CRU in the morning. Subjects' understanding of all study related procedures will be assessed and all remaining questions will be answered. The following sequence of procedures will be followed for all enrolled subjects.

1. Physical exam including vital signs (Blood Pressure, Heart Rate, Weight, Height, Respiration Rate, Temperature)
2. Urine pregnancy test for women of child bearing age. If positive, subjects will be excluded.

Determination of peak oxygen consumption
3. Subjects will complete a continuous VO2 peak bicycle ergometer protocol.

1. Each subject will start peddling on a stationary bike
2. The initial power output (PO) will be set at 20 watts
3. The power output will be increased by 15 watts every 2-minutes until volitional exhaustion.
4. Metabolic data will be collected during the protocol using standard open-circuit spirometric techniques (Viasys Vmax Encore, Yorba Linda, CA)
5. Heart rate was assessed electrocardiographically.
6. VO2 peak will be chosen as the highest VO2 attained during the exercise protocol

On Day 2 of testing

1. Check Vitals (BP, HR, Wt., RR, Temp.)
2. Insert peripheral IV line Baseline renal blood flow measurement using contrast enhanced ultrasonography
3. The Definity vial will be placed at room temperature before being used. It will be activated after shaking the vial using Vialmax® for 45 seconds. It will be used immediately after activation.
4. 0.4 ml of Definity will be mixed in 10 ml of preservative free saline.
5. Infusion of Definity into a peripheral vein will be started at 2 ml/min and titrated for optimal image quality using a minipump (not to exceed 10 ml/min at any time).
6. Baseline contrast ultrasound imaging of right kidney will be performed with low mechanical index (MI) of 0.2.
7. 4 - 5 ultrasound impulses with high MI of 1.0 and duration of 1 second will be used to destruct the microbubbles in the kidney tissue
8. Ultrasound imaging of the kidney with low MI (0.2) will continue immediately after each impulse for several seconds.
9. Infusion of Definity will stop at this point.
10. Vital signs will be monitored every 15 minutes and continuous pulse oximetry will be performed during Definity administration.
11. Vital signs and pulse oximetry will be monitored every 15 minutes until 30 minutes after discontinuation of Definity.
12. A urine dipstick will be performed by the study team 30 minutes after completion of Definity infusion if a sample is available.

Constant load Exercise protocol
13. Subjects will complete 30 minutes of continuous cycling at the power output associated with 85% of VO2peak from the continuous bicycle ergometer protocol. Metabolic data will be collected as described above.
14. Once metabolic parameter are reached, exercise will be stopped and subject will be asked to lie down on the bed Renal Blood flow measurement following exercise using contrast enhanced ultrasonography
15. Immediately after completion of exercise protocol, steps 5 - 12 under day 2 procedures will be repeated.
16. The study procedures will end at this point.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Physiology

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Test Subjects

We will be using the drug Definity that is an approved medication for cardiac contrast enhanced ultrasound to measure the changes in kidney blood flow with exercise in healthy subjects.

Group Type EXPERIMENTAL

Definity

Intervention Type DRUG

During kidney ultrasound, Definity microbubbles will be injected into the vein to see how blood flows through the kidneys

Exercise

Intervention Type OTHER

Kidney Ultrasound

Intervention Type OTHER

This done before and after exercise with the help of Definity to see changes in kidney blood flow

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Definity

During kidney ultrasound, Definity microbubbles will be injected into the vein to see how blood flows through the kidneys

Intervention Type DRUG

Exercise

Intervention Type OTHER

Kidney Ultrasound

This done before and after exercise with the help of Definity to see changes in kidney blood flow

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ultrasound contrast agent or microbubbles stationary Bike Renal Ultrasound examination

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy Adult - 18 to 50 years old
* All ethnicity and genders

Exclusion Criteria

* Pregnancy or lactation
* Active infection
* Hypertension
* Chronic Medication Use except Multi Vitamin Use and Birth Control Medications
* Known history of a right to left intra-cardiac shunt
* Known history of pulmonary hypertension, including porto-pulmonary hypertension
* History of allergies to Definity®
* History of Liver or Kidney Transplant
* Patient on hemodialysis
* Has received iodinated contrast within 72 hours of admission to study
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Virginia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kambiz Kalantarinia

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kambiz Kalantarinia, MD

Role: PRINCIPAL_INVESTIGATOR

University of Virginia, Department of Nephrology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Virginia

Charlottesville, Virginia, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sharon F Johnson, BA

Role: CONTACT

4349823198

Kambiz Kalantarinia, MD

Role: CONTACT

434982-3198

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sharon F Johnson, BA

Role: primary

434-982-3198

Kambiz Kalantarinia, MD

Role: backup

4349823198

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

18220

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Screening of Congenital Anomalies of Kidney
NCT06440499 NOT_YET_RECRUITING